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Rationale: The Saint George’s Respiratory Questionnaire (SGRQ) is often applied to assess 
health related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF). Some 
SGRQ items will inevitably have weaker measurement properties than others when applied to 
this population. This study was conducted to develop an IPF-specific version of the SGRQ.   
Methods: We analysed data from a recently completed trial that enrolled subjects with IPF who 
completed the SGRQ and other meausures at baseline and six months. There were four phases to 
this study: 1) remove items with missing responses and using Rasch analysis on retained items to 
identify fit and refine item response categories; 2) develop a new scoring scheme; 3) test 
agreement between original and revised versions, and test construct validity of the revised SGRQ; 
and 4) reword to finalize the IPF-specific version (SGRQ-I).  
Results: Items were removed due to missing responses (n=6) and misfit to the Rasch model 
(n=10). For certain items, disordered response thresholds were identified and corrected by 
collapsing response categories.  A scoring algorithm was developed to place SGRQ-I scores on  
scale with SGRQ scores.  For any given outcome measure (e.g., pulmonary physiology, 
functional capacity, dyspnea), correlations were similar between pairs that included original 
SGRQ scores and corresponding pairs that included SGRQ-I scores. Internal reliability for each 
SGRQ-I component was comparable to the original SGRQ (Symptoms 0.62; Activities 0.80; 
Impacts 0.85). 
Conclusions: The SGRQ-I contains items from the original SGRQ that are the most reliable for 
measuring HRQL in patients with IPF. 
 
 
 
 
Introduction 
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Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease (ILD) that 
induces  shortness of breath,
1
 resulting in poor quality of life
2,3
 and significantly shortened 
survival for most patients.
4
  Available treatments have no reliable effect on prolonging life.  In 
patients with IPF, health related quality of life (HRQL) is increasingly viewed as an important 
outcome used to assess the effectiveness of treatments and to monitor disease trajectory. HRQL 
refers specifically to a person’s satisfaction with life domains that either affect or are affected by 
his or her health status.
5
  A plethra of generic and condition-specific instruments exsit to measure 
HRQL.  Condition-specific instruments are tailored to patients with the disease of interest, a 
quality that makes them more sensitive to underlying change than generic instruments.
5
  For IPF, 
at this time, no disease-specific measure of HRQL is available, so investigators have used 
generic or non-IPF respiratory-specific instruments to measure HRQL in multi-center trials.
6,7
  
The potential problem is that these instruments may not capture many of the effects IPF has on 
patients’ lives,
8
 thus calling into question whether HRQL results from these trials are valid.  
 
The Saint George’s respiratory questionanire (SGRQ) was originally designed and validated for 
use in patients with chronic obstructive pulmonary disease (COPD).
9
 It has been in existence for 
nearly two decades.  It has been validated for use in other chronic respiratory diseases, and it also 
appears to possess acceptable validity and reliability for use in patients with IPF.
10-12
  However, 
it is enevitable that some SGRQ items have weaker measurement properties than others when 
applied to patient populations other than the one for which it was developed.  Removing such 
items, and modify response options for retained items, would generate a version of the SGRQ 
tailored for patients with IPF.  This study was conducted to refine the content of the SGRQ to  
develop an IPF-specific version.  
 
Methods 
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Overview and Study Sample 
For this study, we used data from a recently completed multi-centered, placebo-controlled trial 
(the Bosentan Use in ILD-1 or BUILD-1)
6
.  In BUILD-1, subjects were randomized to receive 
either bosentan or placebo; for the current study, data from these two groups were pooled.  
Subjects underwent assessments of pulmonary physiology, and completed a six-minute walk test 
(6MWT), the SGRQ, Short Form-36 (SF-36), and Baseline/Transition Dyspnoea Index 
(BDI/TDI) at baseline, six months, and twelve months.  For this analysis, we used data collected 
at baseline and six months.  Subjects in BUILD-1 had very well-defined IPF according to 
international guidelines.
1
    
 
Outcome Measures  
SGRQ.  The SGRQ is a COPD-specific, self-administered HRQL instrument that contains 50 
items divided into three components: Symptoms (n = 8). Activity (n = 16), and Impacts (n = 26).
9
  
Each item has an empirically derived weight, and scores ranging from 0 to 100 are calculated for 
each component, as well as a total score.  Higher scores indicate greater impairment in HRQL.  
 
SF-36.  The SF-36 is a generic health status instrument that contains 36 items tapping eight 
domains that can be separated into two psychometrically-derived summary components—mental 
and physical.  Domain and summary component scores range from 0 to 100; lower scores 
correspond to worse health status. For the summary components, we used scoring algorithms to 
generate linear T-score transformations that place scores on scales with means of 50 and standard 
deviations of 10.  
 
BDI/TDI.  The BDI is a dyspnea questionnaire that evaluates three dimensions: functional 
impairment, magnitude of effort and magnitude of task at a single time point.  It rates the 
  
5 
patient’s breathlessness in each of these domains on a scale from 0 (severe) to 4 (no impairment), 
so total scores range from 0-12.  Although we did not use it here, a companion scale, the 
Transitional Dyspnea Index (TDI), asks respondents to rate how dyspnoea has changed over time 
for each BDI domain.  
 
Forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO), 
were measured as per American Thoracic Society (ATS) guidelines
13,14
 and expressed as 
percentages of the gender, age, and height-adjusted predicted values (i.e., FVC%, DLCO%).  The 
6MWT was performed according to ATS guidelines,
15
 and total distance walked (6MWD) and 
dyspnea (assessed by using the simple Borg Dyspnea index) were recorded.  The average length 
of time between physiological testing and completion of the self-report questionnaires was one 
day.   
 
Study Phases and Statistical Analyses 
Descriptive statistics were generated for baseline data.   
Phase 1: Reducing and refining of the SGRQ: Items with more than 25% missing responses at 
baseline were excluded.  The performance of retained items was tested using Rasch analysis 
(RUMM2020).
16,17
  Each of the three SGRQ components was tested separately.  The Rasch 
model provides a template for testing how well each item contributes to the single construct 
being measured.
16
  Here, a construct refers to a SGRQ component (Symptoms—respiratory 
symptoms, Activity—activities that either cause or are limited by shortness of breath, Impact—
the impact of the disease on factors such as emotional health and sense of control).  Rasch 
analysis uses an iterative process whereby the poorest fitting item is removed and the effect on 
the fit of the remaining is then retested. Item fit was assessed by examining the residual and Chi-
squared fit statistic for each item. The item residual is a summation of the difference between the 
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observed score and the score expected by the model for a particular item and persons. Item 
residuals between ±2.5 indicate adequate fit to the model. The Chi-square (X
2
) compares the 
difference between the observed values with values expected by the model across different levels 
of health for each item. These groups are defined by ordering all patients responses and then 
splitting them into groups of approximately equivalent size across the sample (this is done 
automatically within RUMM2020). A non-significant item Chi-square (p>0.05) indicates good 
fit to the model. Item fit is also assessed graphically using the item characteristic curve (ICC). 
Items with the worst model fit were removed whilst ensuring that the balance of items and 
content validity for each component was retained. The overall fit of each component to the Rasch 
model was determined by examining the person item separation (PSI) which is analogous with 
Cronbach’s alpha, and item-trait interaction chi-square statistic (a non significant p value (>0.05) 
indicates fit to the model).  Rasch analyses were run using RUMM2020 (www.rummlab.com)  
  
Phase 2: Development of a new scoring scheme: Rasch analysis revealed that response options 
for some items needed to be collapsed.  As published previously, for such items, weights from 
collapsed response categories were averaged to produce new weights.
17
  See online supplement 
for new weights.  Linear regression was then used to create scoring algorithms to rescale 
component scores for the refined version of the SGRQ and place them on a scale compatible with 
the original SGRQ.  Specifically, for each component, we regressed SGRQ scores (dependent 
variable) on revised SGRQ scores (independent variable).  Next, we assessed agreement between 
original and revised SGRQ scores using intraclass correlation coefficients (ICCCs) and bland-
Altman plots.
18
  Here, for each component, the difference between scores is plotted against the 
average of the two scores.     
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Phase 3: Cross-sectional and longitudinal validity: Correlations between scores from both the 
original and refined versions of the SGRQ (implementing the scoring as described in Phase 2) 
and other outcome measures were assessed using Pearson correlation coefficients.  We 
analyzed change in original or revised SGRQ component scores from baseline to six months by 
using a mixed-effects model (Proc Mixed procedure in SAS) for each component.  Each model 
considered assessment number (baseline or six-month) as a categorical factor and used an 
unstructured variance-covariance matrix to model the covariance structure among the repeated 
measures by subject.  All available data were included in the analyses.  Besides the Rasch 
analyses, all statistics were run using SAS version 9.1.3 (SAS Institute, Inc., Cary, North 
Carolina)  
  
Phase 4: SGRQ-I: The refined SGRQ is called the SGRQ-I.  Because development of the SGRQ-
I involved the removal of some items and collapsing response categories for other items, we also 
revised the wording and recall period of several items to make their content more practical.
17
 We 
examined internal consistency reliability (Cronbach’s alpha
19
) for each domain of the SGRQ-I, 
and for comparison purposes, for each domain of the original SGRQ.  
 
Results 
Baseline demographic and disease characteristics of the study sample are presented in Table 1. 
 
Phase 1 (See Figure 1) 
Symptoms Items: Two items were removed due to missing data: item 6 (53% missing data) and 
item 8 (33% missing data). The remaining six items were examined for fit to the Rasch model. 
The PSI for this component was 0.71 (“good”).
17
  The response option for the six items had 
disordered thresholds. The disordered thresholds were corrected by combining two or more 
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response categories (details are provided in the online supplement).  Following these changes the 
PSI was 0.63 (acceptable) and the item-trait interaction was x² = 10.4, p=0.58, indicating good fit 
to the Rasch model.  
 
Activity Items: All 16 items were examined with Rasch analysis. The initial PSI was 0.88.  Three 
items (1, 5, and 10) were removed due to a significant x², indicating lack of good-fit to the Rasch 
model. A further three items were removed because their location on the severity scale was high 
(item 1 = 6.14 logits, item 9 = 5.7 logits, and item 8 = 4.2 logits) (details in the online 
supplement).  After removal of these items the PSI 0.83, and the final set demonstrated good fit 
to the model (item-trait interaction x² = 26, p = 0.14).  
 
Impact Items: Four items were initially deleted due to a high number of missing data: item 17 
(45%), item 18 (44%), item 19 (44%), and item 20 (44%). The initial PSI for the remaining 22 
items was 0.85. Items one and two displayed disordered thresholds. These were rectified by 
combining adjacent response options (details in online supplement). Three items (1, 13, and 22) 
demonstrated the worst fit (p<0.0001). These were removed. Item 22 demonstrated good fit to 
the model but it was removed to improve the overall targeting of this component (item logit = 4.6) 
(details in the online supplement). Following these adjustments, the component demonstrated 
good fit to the model (PSI = 0.83 and item-trait interaction x² = 50, p=0.06).  
 
Phase 2 
We adjusted SGRQ-I scores to achieve equivalence with the scale used for SGRQ scoring.  
Specifically, linear regression equations yielded the following: SGRQ-I Symptoms score = -1.08 
+ (0.94 x SGRQ Symptoms score), R
2
=0.88; SGRQ-I Activity score = 4.2 + (0.82 x SGRQ 
Activity score), R
2
=0.95; SGRQ-I Impact score = 3 + (0.82 x SGRQ Impact score), R
2
=0.95; and 
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SGRQ-I Total score = 1.62 + (0.87 x SGRQ Total score), R
2
=0.97.  The ICCCs showed excellent 
reliability: symptoms, 0.97; activities, 0.99; impacts, 0.98; and total, 0.99. Bland-Altman plots 
indicated excellent agreement between scores from the SGRQ and SGRQ-I for each component 
(Figure 2). 
 
Phase 3 
Table 2 shows correlations between SGRQ or SGRQ-I scores and measures of pulmonary 
physiology, dyspnoea, and health status.  For any given outcome measure, correlations were 
similar between pairs that included SGRQ scores and the corresponding pair that included 
SGRQ-I scores.  The weakest correlations were between SGRQ or SGRQ-I scores and measures 
of either pulmonary physiology or functional capacity, and among these, pairs that included 
Symptoms component scores (whether from the SGRQ or SGRQ-I) were weakest of all.  
Considering all outcomes in the study, the only two correlations that did not reach statistical 
significance were for SGRQ Symptoms and 6MWD and for SGRQ-I Symptoms and 6MWD. 
Correlations with dyspnoea and health status (assessed with the SF-36) were moderate-strong, 
and the strongest were between SGRQ or SGRQ-I Activity scores and SF-36 Physical 
Functioning domain scores.  Table 3 shows the similarity in change scores from components of 
the SGRQ or SGRQ-I from baseline to six months. 
 
Phase 4 
The SGRQ-I comprises 34 items, 6 in the Symptoms component, 10 in the Activity component, 
and 18 in the Impact component.  Response categories for each item in the Symptoms 
component were collapsed, such that items in this component from the SGRQ-I contain three 
response options compared with five for the original SGRQ.  All items in the Activity 
component are true/false, so no collapsing was performed—each of the 10 items in this 
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component on the SGRQ-I remains true/false.  Response categories for one item in the Impact 
component were collapsed, such that this item on the SGRQ-I contains two response options 
compared with three for the original SGRQ.  Internal consistency reliability for each component 
of the SGRQ vs. SGRQ-I were as follows: Symptoms 0.66 vs. 0.62; Activity 0.85 vs. 0.80; 
Impact 0.86 vs. 0.85.   
 
Discussion 
We conducted Rasch analyses on HRQL data from a recently completed, randomized, placebo-
controlled trial to develop a new, IPF-specific version of the SGRQ called the SGRQ-I.  We 
developed new item response categories for items with disordered response thresholds, new 
weights for the new response categories, and a scoring algorithm that places SGRQ-I scores on 
scale with the original SGRQ.   
 
Rasch and psychometric testing confirmed that the SGRQ-I has acceptable measurement 
properties.  Specifically, each component of the SGRQ-I had good fit to the Rasch model, 
verifying that items within each component tap a single construct.  The internal consistency 
reliability of each component of the SGRQ-I was similar to the reliabilities for the corresponding 
components of the original SGRQ.  The construct validity of the SGRQ-I was supported by the 
numerous significant correlations between component scores and measures of pulmonary 
physiology, functional capacity, dyspnoea, or health status.  It was reassuring to see that 
coefficients for these correlations were on par with coefficients for corresponding assessments 
for the original SGRQ.  Finally, changes in SGRQ-I component scores over time matched 
changes in original SGRQ component scores quite well. 
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Rasch analysis has gained momentum as an advanced psychometric technique for the robust 
development of health related instruments
20
 and refinement of others
17
. An important feature of 
Rasch analysis is the ability to examine the hierarchical ordering of response options for 
polytomous items (i.e., items with Likert-type response options). We found that the response 
options for a number of items did not follow a logical order. This was resolved by combining 
response options and recalculating weights for such items.  After incorporating these weights, a 
new scoring algorithm was developed to ensure that scores from the SGRQ-I are equivalent to 
scores from the original SGRQ. Our preliminary correlational analyses demonstrate that the new 
scoring system is accurate and reliable.   
 
An advantage of Rasch analysis is the ability to gain information about how items are working, 
both individually and as a scale.  Using Rasch methodology here enabled us to select items that 
generate the most precise measurement of HRQL (in domains tapped by the SGRQ) for patients 
with IPF.  If data fit Rasch model expectations, then a fundamental assumption—that each item 
contributes reliably to the measurement of the single underlying construct—is met.  There are no 
set rules as to whether mis-fitting items should be retained or removed, but like others,
17
 we 
based our decisions on a combination of item-fit statistics, including the PSI, and a requirement 
to maintain the internal consistency reliability and construct validity of the three components.  
 
Our study has limitations.  First, Symptoms component of the SGRQ-I contains a couple of items 
that would seem not to be entirely relevant to patients with IPF.  Specifically, item 4 that asks 
about “attacks of wheezing” and item 5 that asks about “attacks of chest trouble.”  Despite the 
apparent lack of face validity of these items, subjects responded to them, unlike items 6 and 8, 
which were removed because of excessive missing data.  Although removing items 4 and 5 
would seem to have been a reasonable step, doing so detracted substantially from the internal 
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consistency reliability and the PSI, so we decided to retain those them.  Second, it is likely that 
many subjects would have responded differently to certain items whose response category 
structures were modified for the SGRQ-I.  Likert scales are often adopted for questionnaires 
without ever evaluating the ordering of responses.  Disordered options violate the meaning 
implicit in the employed grading system (e.g., for the SGRQ, “Not at all” represents the least 
amount, “Most days a week” represents the most amount, and there are ordered levels of 
increasing amount between the two).  Ignoring disordering yields invalid, unreliable HRQL 
response data. Thus, prospective studies will be needed to assess its responsiveness of the 
SGRQ-I and to determine the minimum change in scores over time that is clinically meaningful.  
Based on the rigorous statistics and thoughtful approach used here, we would expect the SGRQ-I 
to be better targeted to aspects of HRQL and even more responsive to underlying change than the 
original SGRQ in patients with IPF.  Whether an instrument developed from the ground up 
specifically for patients with IPF will be even better targeted and more responsive to change is 
unknown.   
 
In conclusion, we used a systematic, statistical-based method to revise the original SGRQ and 
develop an IPF-specific version called the SGRQ-I.  Both reliability and validity of the SGRQ-I 
are acceptable and comparable to the original SGRQ.  Prospective studies will determine whether 
the specificity of the SGRQ-I is more responsive to underlying change than the SGRQ in patients 
with IPF.  
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Table 1.  Demographic and baseline disease characteristics of  
 subjects in BUILD-1 
 
Variable N=158 
 
Age 
 
65.12 (8.93) 
 
BMI 
 
29.18 (4.31) 
 
Gender M/F 
 
73/27 
 
Smoking status (%) 
     Non/Current  
 
 
98/2 
 
Race (%)   
     Caucasian 
     Black      
     Asian 
     Hispanic 
     Other 
 
 
92 
  2 
  1 
  4 
  1 
 
Baseline FVC in Liters 
 
2.64 (.73) 
 
Baseline FVC% 
 
66.97 (12.17) 
 
Baseline DLCO% 
 
40.98 (10.08) 
 
6MWD in meters 
 
373.3 (81.2) 
 
BDI Total 
 
6.8 (2.1) 
 
Data are presented as means (SD) or  
percentages.  BMI=body mass index; FVC= 
forced vital capacity; FVC%=percent  
predicted FVC; DLCO%=percent predicted 
diffusing capacity of the lung for carbon 
monoxide; BDI=Baseline Dyspnea Index 
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Table 2.  Correlations between either Original SGRQ or SGRQ-I scores and other 
outcome measures. 
 
  Symptoms  Activity  Impact Total 
  
Original 
 
SGRQ-I 
 
Original 
 
SGRQ-I 
 
Original 
 
 SGRQ-I 
 
 Original 
 
SGRQ-I 
 
FVC% 
 
-0.27* 
 
-0.25† 
 
-0.31† 
 
-0.30† 
 
-0.30† 
 
-0.31† 
 
-0.34† 
 
-0.33† 
 
DLCO% -0.23* -0.25† -0.34† -0.33† -0.38† -0.36† -0.38† -0.37† 
 
6MWD -0.14 -0.12 -0.32† -0.30† -0.24* -0.26† -0.28* -0.28* 
 
Borg 0.35† 0.33† 0.45† 0.47†* 0.40† 0.40† 0.45† 0.46† 
 
BDI -0.39† -0.42† -0.72† -0.68† -0.61† -0.61† -0.68† -0.67† 
 
SF-36 
   PF 
   RP 
   BP 
   GH 
   VT 
   SF 
   RE 
   MH 
   PCS 
   MCS 
 
-0.43† 
-0.40† 
-0.44† 
-0.47† 
-0.46† 
-0.37† 
-0.25† 
-0.27* 
-0.52† 
-0.25* 
 
-0.44† 
-0.38† 
-0.38† 
-0.44† 
-0.41† 
-0.38† 
-0.26† 
-0.24† 
-0.49† 
-0.24* 
 
-0.80† 
-0.58† 
-0.46† 
-0.60† 
-0.61† 
-0.58† 
-0.43† 
-0.32† 
-0.74† 
-0.38† 
 
-0.79† 
-0.59† 
-0.46† 
-0.59† 
-0.59† 
-0.56† 
-0.44† 
-0.33† 
-0.73† 
-0.38† 
 
-0.64† 
-0.58† 
-0.51† 
-0.64† 
-0.61† 
-0.62† 
-0.57† 
-0.45† 
-0.63† 
-0.55† 
 
-0.66† 
-0.55† 
-0.51† 
-0.62† 
-0.60† 
-0.62† 
-0.55† 
-0.46† 
-0.62† 
-0.55† 
 
-0.73† 
-0.62† 
-0.53† 
-0.67† 
-0.64† 
-0.62† 
-0.52† 
-0.42† 
-0.71† 
-0.49† 
 
-0.74† 
-0.60† 
-0.53† 
-0.65† 
-0.63† 
-0.63† 
-0.53† 
-0.43† 
-0.71† 
-0.50† 
 
*p<0.01; †p<0.0001; SGRQ-I=IPF-specific version of Saint George’s Respiratory 
Questionnaire; FVC%=percent predicted forced vital capacity; DLCO%=percent 
predicted diffusing capacity of the lung for carbon monoxide; 6MWD=distance 
walked during the six-minute walk test; Borg=Borg Dyspnea Index; BDI=Baseline 
Dyspnea Index; SF-36=Medical Outcomes Study Short-Form 36-Item Instrument; 
PF=Physical Functioning; RP=Role Physical; BP=Bodily Pain; GH=General Health; 
VT=Vitality; SF=Social Functioning; RE=Role Emotional; MH=Mental Health; 
PCS=Physical Component Summary; MCS=Mental Component Summary  
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Table 3.  Change scores over six months for original SGRQ and SGRQ-I 
 
 
 Original SGRQ P value SGRQ-I P value 
     
Symptoms -4.75 (1.83) 0.01 -2.58 (1.36) 0.06 
 
Activity 
 
1.19 (1.27) 
 
0.39 
 
 
1.17 (1.34) 
 
 
0.35 
Impact -3.28 (1.38) 0.02 -2.56 (1.27) 
 
0.04 
Total -1.85 (1.17) 0.12 -1.64 (1.11) 0.14 
 
Data reported as mean (standard error); SGRQ=Saint George’s Respiratory 
Questionnaire; SGRQ-I=IPF-specific version of the SGRQ; P value for significance 
of change between baseline and six-month scores 
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50 items
Rasch
Analysis
6 items removed due to missing responses
Symptoms: 2 items                                               
Activity: 0 items                                               
Impact: 4 items
Symptoms
0 items 
removed, 
response 
categories 
reordered 
for all 6 
items
Activity
6 items 
removed 
Impact
4 items 
removed, 
response 
categories 
reordered 
for one 
item
Remaining 34 items compose the SGRQ-I       
Symptoms Component: 6 items                                     
Activity Component: 10 items                                    
Impact Component: 18 items
 
 
 
Figure 1: Process of item removal 
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Figure 1: Difference between original SGRQ and SGRQ-I scores plotted against the 
mean of the original SGRQ and SGRQ-I scores. 
